Baird Medical's First U.S. MWA Case for Thyroid Nodules
January 12, 2024 — Baird Medical marked a significant milestone by completing its first-ever Microwave Ablation (MWA) surgery for a thyroid nodule in the United States. This landmark procedure was conducted by Dr. Alireza Falahati-Nini, a board-certified endocrinologist and interventional thyroidologist, at Utah Endocrinology Associates in Salt Lake City, Utah.
The procedure was conducted less than two months after Baird Medical obtained FDA clearance for its advanced MWA system in November 2023. Dr. Falahati performed the ablation on a patient with a symptomatic thyroid nodule using Baird’s state-of-the-art ablation needle, which precisely targets nodules while preserving healthy thyroid tissue.
A Leap Forward in Thyroid Nodule Management
MWA technology offers patients a minimally invasive alternative to conventional surgical excision. By delivering therapeutic microwave energy directly into the nodule, the treatment minimizes scar formation, shortens recovery time, and eliminates the need for lifelong hormone replacement therapy commonly associated with surgery.
Dr. Falahati expressed his optimism about the new treatment modality: “The success of this first MWA case represents a leap forward in our ability to treat thyroid nodules effectively. This technology enables us to offer patients a safer and more efficient alternative, and I look forward to performing many more similar procedures in the near future.”
A New Era for Thyroid Treatments in the U.S.
With an estimated 30-50% of adults developing thyroid nodules in their lifetime, the adoption of minimally invasive ablation techniques like MWA is expected to significantly transform clinical practice. By avoiding the complications and extended recovery periods associated with traditional surgery, Baird Medical’s MWA technology provides a compelling treatment option for many patients.
“We congratulate Dr. Falahati and his team for setting a new standard in thyroid care,” said Ms. Haimei Wu, Founder and CEO of Baird Medical. “This milestone highlights our commitment to bringing innovative, patient-centric solutions to the U.S. market. We are excited to see how our technology will continue to expand treatment possibilities for thyroid disorders.”
Disclaimer: This post may contain forward-looking statements regarding Baird Medical’s future plans, market expansion, and expected performance of its products. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results could differ materially from those anticipated in these statements. Baird Medical undertakes no obligation to update any forward-looking statements, except as required by law.
This post is for informational purposes only. Please consult a healthcare professional for personalized treatment recommendations.